Advertisement

Topics

Genkyotex Company Profile

02:21 EDT 25th June 2018 | BioPortfolio

Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyotex has identified novel NOX inhibitors with the potential to treat disease areas with a high clinical need and large market potential. Genkyotex was founded in 2006 by scientists from Switzerland, the USA and Japan, with backing from Geneva incubator Eclosion. A Series C round was closed in 2011 led by Edmond de Rothschild Investment Partners and joined by other new investors Vesalius BioCapital and MP Healthcare Venture Management. Further information can be found at: www.genkyotex.com.


News Articles [5 Associated News Articles listed on BioPortfolio]

Genkyotex Announces 2017 Annual Financial Results

Operating expenses in line with Company's acceleration of drug development activities and corporate growth Genkyotex's cash runway extends through Q1 2019 Two Phase II clinical trials ongoing for ...

Genkyotex to Present Corporate Overview at 30th Annual ROTH Conference

Regulatory News: Genkyotex (Paris:GKTX) (Brussels:GKTX) (Euronext Paris Brussels: FR00011790542 GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that it will par...

Genkyotex Reports December 31, 2017 Cash Position and Provides Business Update

Cash, cash equivalents and liquid investments of €14.6 million as of December 31st, 2017, in line with Company's expectations Phase 2 trial of GKT831 in Primary Biliary Cholangitis on track with i.....

Genkyotex Reports March 31, 2018 Cash Position and Provides Business Update

Cash and cash equivalents of €12.5 million as of March 31st, 2018, in line with expectations Cash runway to Q3 2019 Company now expects interim results from phase 2 trial of GKT831 in Primary Bili.....

GenKyoTex SA GKTX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12032018] Prices from USD $250

SummaryGenKyoTex SA GenKyoTex, formerly Genticel SA is a drug company that develops NOX therapies. The company develops targeted NOX inhibitors. It develops molecule therapeutics that inhibits the NOX...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Genkyotex

Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyot...

More Information about "Genkyotex" on BioPortfolio

We have published hundreds of Genkyotex news stories on BioPortfolio along with dozens of Genkyotex Clinical Trials and PubMed Articles about Genkyotex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genkyotex Companies in our database. You can also find out about relevant Genkyotex Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...


Corporate Database Quicklinks



Searches Linking to this Company Record